Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.J. Bailey.
Potential new treatments for type 2 diabetes.
Trends Pharmacol Sci, 21 (2000), pp. 259-265
[2.]
A.A. Parulkar, M.L. Pendregrass, R. Granda-Ayala, T.R. Lee, V.A. Fonseca.
Nonhypoglycemic effects of tiazolidinediones.
Ann Intern Med, 134 (2001), pp. 61-71
[3.]
M. Wang, S.C. Wise, T. Leff, T.Z. Su.
Troglitazone, and antidiabetic agent, inhibts cholesterol biosyntesis through a mechanism independent of PPARgamma.
Diabetes, 48 (1999), pp. 245-260
[4.]
M. Hanefeld.
The metabolic syndrome: roots, myths, and facts.
The Metabolic Syndrome, pp. 13-24
[5.]
T.J. Lyons, A.J. Jemkins.
Lipoprotein glycation and its metabolic consequences.
Curr Opin Lipidol, 8 (1997), pp. 174-180
[6.]
S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[7.]
S.H. Saydah, C.M. Loria, M.S. Eberhardt, F.L. Brancati.
Subclinical states of glucose intolerance and risk of death in the U.S.
Diabetes Care, 24 (2001), pp. 447-453
[8.]
B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, et al.
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
Diabetes Care, 24 (2001), pp. 683-689
[9.]
J.F. Ascaso, P. Romero, J.T. Real, A. Priego, C. Valdecabres, R. Carmena.
Cuantificación de insulinorresistencia con los valores de insulina basal e índice HOMA en una población no diabética.
Med Clin (Barc), 117 (2001), pp. 530-533
[10.]
American Diabetes Association. Management of dyslipidemia in adults with diabetes.
Diabetes Care, 24 (2001), pp. S58-S61
[11.]
M.R. Lakshman, D.J. Reda, B.J. Materson, W.C. Cushman, E.D. Freis.
Diuretics and betablockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Arch Intern Med, 159 (1999), pp. 551-558
[12.]
B. Kennon, M. Fisher.
HOPE study. Practical consequences for diabetic patients.
Pract Diab Int, 17 (2000), pp. 191-194
[13.]
C.M. Nass, R.S. Blujmenthal.
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Am J Manag Care, 6 (2000), pp. S1247-S1256
[14.]
A.D. Marais.
Therapeutic modulation of low-density lipoprotein size.
Curr Opin Lipidol, 11 (2000), pp. 597-602
[15.]
S. Sunayama, Y. Watanabe, H. Daida, H. Yamaguchi.
Thiazolidienediones, dyslipidaemia and insulin resistance síndrome.
Curr Opin Lipidol, 11 (2000), pp. 397-402
[16.]
A.B. King.
A comparison in a clinical setting of the efficacy and size effects of three thiazolidinediones.
Diabetes Care, 23 (2000), pp. 556-557
[17.]
G. Boden.
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
Diabetes, 46 (1997), pp. 3-10
[18.]
G. Boden.
Free fatty acids – The link between obesity, insulin resistance and type 2 diabetes.
Endocr Pract, 7 (2001), pp. 44-51
[19.]
A.O. Rantala, H. Kauma, M. Lilja, M.J. Savolainen, A. Reunanen, Y.A. Kesaniemi.
Prevalence of the metabolic syndrome in drug treated hypertensive patients and control subjects.
J Intern Med, 245 (1999), pp. 163-174
[20.]
M. Esler, M. Rumantir, Wieser Glen, D. Kaye, J. Hasting, G. Lamberg.
Sympathetic nervous system and insulin resistance: from obesity to diabetes.
Am J Hypertens, 14 (2001), pp. S304-S309
[21.]
L.N. Kaufman, M.M. Peterson, L.M. DeGraange.
Pioglitazone attenuates diet induced hypertension in rats.
Metabolism, 44 (1995), pp. 1105-1109
[22.]
A.B. Walker, P.D. Chattington, R.E. Buckinham, G. Williams.
The thiazolidinedione rosiglitazone lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
Diabetes, 24 (1999), pp. 170-175
[23.]
E. Imano, T. Kanda, Y. Nakatani, T. Nishida, K. Akai, M. Motomura, et al.
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Diabetes Care, 2 (1998), pp. 2135-2139
[24.]
J. Egido, A. Hernandez Presa, J. Tuñón, L.M. Blanco-Colio, Y. Suzuki, J.J. Plaza, et al.
El factor de transcripción B (NFkB) y las enfermedades cardiovasculares.
Cardiovasc Risk Factors (ed. española), 9 (2000), pp. 92-103
[25.]
I. Golovchenko, M.L. Goalstone, P. Watson, M. Brownlee, B. Draznin.
Hyperinsulinemia enhances transcriptional activity of nuclear factor- kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells.
Circ Res, 87 (2000), pp. 722-724
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.